Curis Inc (CRIS)

Currency in USD
1.6700
+0.0700(+4.38%)
Closed·
After Hours
1.6400-0.0300(-1.80%)
·
CRIS Scorecard
Full Analysis
Suffers from weak gross profit margins
CRIS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.56001.7200
52 wk Range
1.02008.2900
Key Statistics
Prev. Close
1.67
Open
1.71
Day's Range
1.56-1.72
52 wk Range
1.02-8.29
Volume
62.66K
Average Volume (3m)
114.15K
1-Year Change
-65.28%
Book Value / Share
-0.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRIS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.3333
Upside
+878.04%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile

Curis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Curis Inc Company Profile

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis Inc Earnings Call Summary for Q2/2025

  • Curis Inc's Q2 2025 net loss reduced to $8.6M ($0.68/share) from $11.8M ($2.03/share) in Q2 2024; stock rose 10% to $1.76 in premarket trading
  • Cash runway extended into 2026 after $6M offering; R&D and administrative expenses decreased significantly year-over-year
  • Company to present AML triplet study data at ASH conference in December; plans to initiate CLL study by year-end with initial data expected mid-2026
  • CEO highlighted commitment to improving oncology care, but expressed concern over FDA regulatory uncertainty
  • Analysts bullish despite weak Financial Health Score; price targets range from $12 to $20 per share
Last Updated: 05/08/2025, 17:00
Read Full Transcript

Compare CRIS to Peers and Sector

Metrics to compare
CRIS
Peers
Sector
Relationship
P/E Ratio
−0.5x−1.5x−0.5x
PEG Ratio
−0.02−0.020.00
Price/Book
−3.0x0.9x2.6x
Price / LTM Sales
1.8x41.5x3.3x
Upside (Analyst Target)
-400.7%42.8%
Fair Value Upside
Unlock40.5%6.5%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.3333
(+878.04% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-1.25 / -1.20
Revenue / Forecast
2.38M / --
EPS Revisions
Last 90 days

CRIS Income Statement

People Also Watch

264.75
AVAV
-1.19%
45.130
SMR
+4.03%
52.570
ASTS
+2.32%
8.55
CRNC
-0.12%
84.09
OKLO
+10.05%

FAQ

What Stock Exchange Does Curis Trade On?

Curis is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Curis?

The stock symbol for Curis is "CRIS."

What Is the Curis Market Cap?

As of today, Curis market cap is 20.11M.

What Is Curis's Earnings Per Share (TTM)?

The Curis EPS (TTM) is -6.03.

From a Technical Analysis Perspective, Is CRIS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Curis Stock Split?

Curis has split 2 times.

How Many Employees Does Curis Have?

Curis has 34 employees.

What is the current trading status of Curis (CRIS)?

As of 06 Aug 2025, Curis (CRIS) is trading at a price of 1.67, with a previous close of 1.67. The stock has fluctuated within a day range of 1.56 to 1.72, while its 52-week range spans from 1.02 to 8.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.